At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 557 enrolled
Drug / intervention
Eslicarbazepine acetate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) as Therapy for Patients With Painful Diabetic Neuropathy: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Eslicarbazepine acetate and Placebo for Painful Diabetic Neuropathy. Completed, enrolled 557 participants.
Detailed Summary
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with painful diabetic neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPainful Diabetic Neuropathy
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
Primary CompletionNov 2008
First PostedSep 2009
TodayJul 2026
First PostedSep 21, 2009
Enrollment StartNov 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.8 years ago
Interventions
Eslicarbazepine acetatedrug
Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
Placebodrug
oral route